News | Breast Imaging | March 29, 2018

ACR Recommends More Aggressive Breast Cancer Screening for Higher-Than-Average-Risk Women

All women recommended to undergo risk assessment by age 30; association now recommends annual breast MRI for particular subgroups

ACR Recommends More Aggressive Breast Cancer Screening for Higher-Than-Average-Risk Women

March 29, 2018 — The American College of Radiology (ACR) released new breast cancer screening guidelines recommending all women, especially black women and those of Ashkenazi Jewish descent, should undergo risk assessment by age 30. Assessing risk at this age would allow women at higher risk to be identified and begin earlier and more aggressive screening for breast cancer. In a separate recent analysis[i] from Harvard, black, Hispanic and Asian women have peak incidence of breast cancer in their 40s and should begin screening at least by age 40.

The ACR reaffirmed recommendations for annual breast magnetic resonance imaging (MRI) in the following groups, with slight refinements:

  • 1) Women with known or disease-causing BRCA1 mutation (or their untested first-degree relatives) should begin annual MRI at age 25. If MRI is performed annually, there is emerging evidence that the benefit of mammography is relatively small in such women prior to the age of 40;
  • 2) Women with other known disease-causing mutations (or their untested first-degree relatives), and those with a calculated lifetime risk of 20 percent or more, should begin annual MRI between age 25 and 30. Annual mammography is of benefit in those with BRCA2 mutations;
  • 3) Women with prior chest/mantle radiation therapy (cumulative dose of ≥ 10 Gy) before age 30 should begin MRI and annual mammography at age 25 or at least 8 years after completion of radiation, whichever is latest; and
  • 4) Women with a calculated lifetime risk of breast cancer of ≥ 20 percent. The Tyrer-Cuzick model was discussed as the most comprehensive and consistently accurate model for predicting risk and now includes fibroglandular breast density as a risk factor, though all models may over- or underestimate risk for a given individual.

The ACR newly endorses annual screening MRI in addition to annual mammography or tomosynthesis for women in the following situations (provided the patient has not had bilateral mastectomy):

  • Women with a personal history of breast cancer and dense breasts; and
  • All women diagnosed by age 50. A personal history of breast cancer is not included in risk models, but all women diagnosed with breast cancer at or before age 50 and treated with breast-conserving therapy have a ≥ 20 percent risk for a new breast cancer.

The ACR suggests annual MRI be considered in addition to annual mammography or tomosynthesis in women with a history of lobular carcinoma in situ (LCIS) or prior atypia (ADH, ALH, atypical papilloma), especially if other risk factors are present, though further study of the benefit of MRI is needed.

In women who meet guidelines for MRI screening but are unable to tolerate it and who have dense breasts, the ACR suggests ultrasound be considered in addition to annual mammography. Tomosynthesis is expected to reduce the benefit of supplemental screening ultrasound, depicting about half of the cancers that would have been seen only on ultrasound after 2-D mammography, though further study is warranted. If MRI is performed, there is no benefit to screening ultrasound.

For more information: www.acr.org

References

I. Stapleton SM, Oseni TO, Bababekov YJ, Hung Y, Chang DC. Race/Ethnicity and Age Distribution of Breast Cancer Diagnosis in the United States. JAMA Surg. Published online March 07, 2018. doi:10.1001/jamasurg.2018.0035

 

Related Content

Lunit Receives Korea MFDS Approval for Lunit Insight MMG
News | Artificial Intelligence | August 19, 2019
Lunit has announced Korea Ministry of Food and Drug Safety (MFDS) approval of its artificial intelligence (AI) solution...
Imago Systems Announces Collaboration With Mayo Clinic for Breast Imaging

Image courtesy of Imago Systems

News | Mammography | August 14, 2019
Image visualization company Imago Systems announced it has signed a know-how license with Mayo Clinic. The multi-year...
Artificial Intelligence Could Yield More Accurate Breast Cancer Diagnoses
News | Artificial Intelligence | August 13, 2019
University of California Los Angeles (UCLA) researchers have developed an artificial intelligence (AI) system that...
Lake Medical Imaging Selects Infinitt for Multi-site RIS/PACS
News | PACS | August 09, 2019
Infinitt North America will be implementing Infinitt RIS (radiology information system)/PACS (picture archiving and...
Volpara to Distribute Screenpoint Medical's Transpara AI Solution
News | Breast Imaging | August 02, 2019
Volpara Solutions and ScreenPoint Medical BV signed an agreement under which Volpara will sell ScreenPoint's Transpara...
Ikonopedia Releases Automated Combined Reporting Package at AHRA
News | Mammography Reporting Software | July 26, 2019
Ikonopedia showcased its recently released Automated Combined Reporting package and its entire suite of structured...
Hologic Partners With MagView to Develop Unifi EQUIP Solution
Technology | Mammography Reporting Software | July 25, 2019
Hologic announced a partnership with mammography information solutions provider MagView to develop Unifi EQUIP, an...
Fujifilm Releases Tomosynthesis Biopsy Option for Aspire Cristalle Mammography System
Technology | Breast Biopsy Systems | July 24, 2019
Fujifilm Medical Systems U.S.A. Inc. recently expanded its breast imaging solutions with the launch of its...
IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...